162 related articles for article (PubMed ID: 37389827)
21. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C; Cheah CY; Eyre TA; Tucker D; Klener P; Giné E; Crucitti L; Muzi C; Iadecola S; Infante G; Bernard S; Auer RL; Pagani C; Duglosz-Danecka M; Mocikova H; van Meerten T; Cencini E; Marin-Niebla A; Williams ME; Angelillo P; Nicoli P; Arcari A; Morello L; Mannina D; Vitagliano O; Sartori R; Chiappella A; Sciarra R; Stefani PM; Dreyling M; Seymour JF; Visco C
Blood; 2022 Oct; 140(17):1907-1916. PubMed ID: 35789260
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and prognostic potential of the macrophage specific receptor CD163 in inflammatory diseases.
Buechler C; Eisinger K; Krautbauer S
Inflamm Allergy Drug Targets; 2013 Dec; 12(6):391-402. PubMed ID: 24090317
[TBL] [Abstract][Full Text] [Related]
23. Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients.
Kjærgaard AG; Rødgaard-Hansen S; Dige A; Krog J; Møller HJ; Tønnesen E
PLoS One; 2014; 9(3):e92331. PubMed ID: 24637679
[TBL] [Abstract][Full Text] [Related]
24. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.
Hsi ED; Jung SH; Lai R; Johnson JL; Cook JR; Jones D; Devos S; Cheson BD; Damon LE; Said J
Leuk Lymphoma; 2008 Nov; 49(11):2081-90. PubMed ID: 19021050
[TBL] [Abstract][Full Text] [Related]
25. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Nam SJ; Go H; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2014 Nov; 55(11):2466-76. PubMed ID: 24397616
[TBL] [Abstract][Full Text] [Related]
26. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding.
Møller HJ; Nielsen MJ; Maniecki MB; Madsen M; Moestrup SK
Immunobiology; 2010 May; 215(5):406-12. PubMed ID: 19581020
[TBL] [Abstract][Full Text] [Related]
27. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.
Hiraoka A; Horiike N; Akbar SM; Michitaka K; Matsuyama T; Onji M
J Gastroenterol; 2005 Jan; 40(1):52-6. PubMed ID: 15692789
[TBL] [Abstract][Full Text] [Related]
28. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
29.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
30. Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.
Matsuki E; Bohn OL; El Jamal S; Pichardo JD; Zelenetz AD; Younes A; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):572-580. PubMed ID: 30106758
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
32. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
Tornai T; Vitalis Z; Sipeki N; Dinya T; Tornai D; Antal-Szalmas P; Karanyi Z; Tornai I; Papp M
Liver Int; 2016 Nov; 36(11):1628-1638. PubMed ID: 27031405
[TBL] [Abstract][Full Text] [Related]
33. Utility of Macrophage-activated Marker CD163 for Diagnosis and Prognosis in Pulmonary Tuberculosis.
Suzuki Y; Shirai M; Asada K; Miwa S; Karayama M; Nakamura Y; Inui N; Shirai T; Hayakawa H; Baba S; Suda T
Ann Am Thorac Soc; 2017 Jan; 14(1):57-64. PubMed ID: 27684274
[TBL] [Abstract][Full Text] [Related]
34. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
Hsi ED; Li H; Nixon AB; Schöder H; Bartlett NL; LeBlanc M; Smith S; Kahl BS; Leonard JP; Evens AM; Scott DW; Rimsza LM; Friedberg JW
Blood; 2019 Apr; 133(16):1762-1765. PubMed ID: 30723079
[TBL] [Abstract][Full Text] [Related]
36. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.
Medrek C; Pontén F; Jirström K; Leandersson K
BMC Cancer; 2012 Jul; 12():306. PubMed ID: 22824040
[TBL] [Abstract][Full Text] [Related]
37. Soluble CD163 Levels and CD163+CD14+ Monocyte/Macrophage Counts in Patients with Asthma.
Zhi Y; Gao P; Li W; Gao F; Zhang J; Lin H; Zhang J
Iran J Immunol; 2018 Sep; 15(3):239-245. PubMed ID: 30246699
[TBL] [Abstract][Full Text] [Related]
38. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
Assis-Mendonça GR; Fattori A; Rocha RM; Lourenço GJ; Delamain MT; Nonogaki S; de Lima VCC; Colleoni GWB; de Souza CA; Soares FA; Lima CSP; Vassallo J
BMC Cancer; 2021 Mar; 21(1):209. PubMed ID: 33648463
[TBL] [Abstract][Full Text] [Related]
39. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
[TBL] [Abstract][Full Text] [Related]
40. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
Goy A; Kalayoglu Besisik S; Drach J; Ramchandren R; Robertson MJ; Avivi I; Rowe JM; Herbrecht R; Van Hoof A; Zhang L; Cicero S; Fu T; Witzig T
Br J Haematol; 2015 Aug; 170(4):496-503. PubMed ID: 25921098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
